NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
about
Towards a Better Understanding of the Molecular Mechanisms Involved in Sunlight-Induced MelanomaThe evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinibPhytochemicals for the Management of MelanomaMelanoma: oncogenic drivers and the immune systemTherapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Circulating serologic and molecular biomarkers in malignant melanomaCombined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cellsUncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAFClinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertensionImproving melanoma classification by integrating genetic and morphologic featuresFrequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanomaMelanoma epidemiology, biology and prognosis.Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenibMolecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome.WNT/β-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner.Variation of mutant allele frequency in NRAS Q61 mutated melanomas.Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma.Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell linesNew strategies in melanoma: molecular testing in advanced disease.Understanding the biology of melanoma and therapeutic implicationsMelanocytic nevi, nevus genes, and melanoma risk in a large case-control study in the United Kingdom.NRAS mutations are rare in colorectal cancer.Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish.Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.Multiparametric analysis of cell-free DNA in melanoma patientsClinical correlates of NRAS and BRAF mutations in primary human melanoma.Targeted therapy for melanoma: a primer.Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model.Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.Driver mutations in melanoma: lessons learned from bench-to-bedside studiesDabrafenib and its potential for the treatment of metastatic melanoma.Automated universal BRAF state detection within the activation segment in skin metastases by pyrosequencing-based assay U-BRAF(V600)Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanomaGenotyping of cutaneous melanoma.KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 casesGenetic and morphologic features for melanoma classification
P2860
Q24806589-28E8F048-9237-47CD-B97E-57CF578911BDQ26744335-F03EB3A6-162D-4C41-B062-44D5DE417DC1Q26766708-025BED21-F326-4E3E-98AD-346188C399FDQ26775598-5CD163C7-64EF-49AD-8B57-5823C72D7E85Q26782222-40888EE1-128B-415F-BB14-5C08E87E0B2FQ27020946-8D8B181F-5990-4148-95C8-1CDE935551FEQ27852093-617EADDF-0E84-4527-8F98-682A587F5320Q27852445-ECA67D13-72B3-44CD-82A1-DB463E14A230Q28393898-518A8E0F-345A-4A9E-91E9-C6C36451E0C5Q28474973-A22FC1A9-90D4-468C-B528-3DAFDB678A28Q28728389-AE58883B-E137-427D-A060-81451E6E8984Q33340639-1F97085A-20DD-42BE-8B54-FD813AD01129Q33387548-80123558-B954-4DDF-987D-8647CBA28D5FQ33698718-23E47411-9F9A-4BE3-89B7-AEEE73FC9277Q33758211-68B17233-6792-41C5-82D1-CA52190B3AA0Q33778554-561643F2-30F3-4B6F-87D2-B0935B735A78Q33785885-1C60008E-EB54-4538-93B4-ADFFB6DEBA39Q33862539-32A462FF-072D-494C-A6EE-6CF2A8A1ECCDQ33873686-7B7E057E-5089-4F63-BC8E-53ED3C9436E3Q33913913-6AA9E5ED-E050-4443-B70C-1B6809688290Q33943660-487BFA7E-6688-4820-9EA6-EE93AC65E959Q33978378-683C1B02-2D1F-4540-AC29-00A17319F369Q34071271-D1A45343-3012-446B-81F3-8FD9CF121857Q34091172-E3AD86C0-699E-4408-84F1-1B85A2B1E2DAQ34144327-6A015981-EF91-43D0-8D3C-4B102B84FA41Q34207132-DD82B3C1-2F00-4498-8A84-56D698A74B63Q34220097-3DB57877-D1DE-46B1-9F9B-25DCD722C15FQ34499759-F57F181A-C1A8-4FF4-9D6E-3D421A951A80Q34500495-4EB1FE58-EC6A-42A1-B91A-74F6D7FF7683Q34540273-189F5A57-A876-43A0-A0A7-5D9857D64A2DQ34633455-0974BC5A-B509-4672-AABF-BFE2DBEB573EQ34633885-96D865B1-AE9C-45EB-AC87-24ACFC212006Q34634256-D59EAA2B-6003-4B25-98FD-F154B0FB1CD5Q34639532-C681B615-EB07-4E2D-971F-C11C1AD474C4Q34646614-6131BCD4-C268-4318-9E41-66562551A329Q34650871-8BBAFAEB-98AF-4D92-AE5B-776401EB93A1Q34662717-816EDE5D-A310-4E3D-9E2D-1FE003F2995AQ34667738-6B22CCEB-3793-4A93-A105-5636C6BB289FQ34824234-9203BFA6-D61C-4FFB-B408-E882C3152D64Q35024226-47C6D2ED-BE1B-4A34-99E1-367DA16E8539
P2860
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
NRAS and BRAF mutations arise ...... throughout tumor progression.
@ast
NRAS and BRAF mutations arise ...... throughout tumor progression.
@en
type
label
NRAS and BRAF mutations arise ...... throughout tumor progression.
@ast
NRAS and BRAF mutations arise ...... throughout tumor progression.
@en
prefLabel
NRAS and BRAF mutations arise ...... throughout tumor progression.
@ast
NRAS and BRAF mutations arise ...... throughout tumor progression.
@en
P2093
P1476
NRAS and BRAF mutations arise ...... d throughout tumor progression
@en
P2093
Anton Platz
Johan Hansson
Katarina Omholt
Lena Kanter
Ulrik Ringborg
P304
P407
P577
2003-12-01T00:00:00Z